Clinical trials: Mental Depression
Anxiety, Depression in Adolescence
Co-designing Adaptations of a Digital Mental Health Intervention (Wysa) for Adolescent Girls With Anxiety or Depression in Rural India
The goal of this study is to culturally and contextually adapt Wysa, an evidence-based AI-powered digital mental health intervention (DMHI), for adolescent girls (ages 13-18) with symptoms of anxiety and/or depression in rural…
- Conditions
- Anxiety, Depression in Adolescence, Anxiety Disorder of Adolescence
- Trial name
- NCT07595029
- Testing
- Digital psychosocial tool
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Wysa
Schizophrenia, Bipolar Disorder
Physician Survey on Monitoring of Patients Treated With Quetiapine
A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT01795326
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major Depression
A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder
The purpose of the study is to assess whether treatment with SR58611A can prevent relapse of depressive symptoms in patients with major depressive disorder.
- Trial name
- CALYPSO (NCT00345098)
- Testing
- SR58611A
- Where
- 13 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 704 people
- Sponsor
- Sanofi
Depressive Disorder
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- Orvepitant MDD (NCT00880048)
- Testing
- orvepitant
- Where
- 32 sites in United States, Canada
- Volunteers
- 343 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder (MDD)
A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
The purpose of this study is to determine if LY03005 is effective and safe in improve MADRS score, as compared to placebo (no medicine) in participants with Major Depressive Disorder (MDD)
- Trial name
- NCT04853407
- Testing
- LY03005 extended-release tablet
- Where
- China
- Volunteers
- 558 people
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.
- Trial name
- NCT01432457
- Testing
- desvenlafaxine succinate sustained-release 50 mg/day, desvenlafaxine succinate sustained-release 100 mg/day
- Where
- 61 sites in United States
- Volunteers
- 924 people
- Sponsor
- Pfizer
Depressive Disorder
TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of TAK-653 when administered as single and multiple oral doses at escalating dose levels in healthy participants.
- Trial name
- NCT02561156
- Testing
- TAK-653
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Depression
A Feasibility Study of an AI-Powered Clinical Decision Aid for Personalized Depression Treatment Selection
The Clinical Decision Aid (CDA) is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of possible…
- Trial name
- NCT04061642
- Testing
- Clinical Decision Aid
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Aifred Health Inc.
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
Depressive Disorder
Seasonal Affective Depression (SAD) Study
A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
- Trial name
- NCT00069459
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Depression Bipolar
Study Evaluating Bifeprunox in Bipolar Depression
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of Bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
- Trial name
- NCT00245973
- Testing
- Bifeprunox
- Where
- 40 sites in United States
- Volunteers
- 380 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
- Trial name
- NCT00358631
- Testing
- SSR149415
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Sanofi
Depression, Anhedonia
PRISM Neurofeedback Training for MDD Anhedonic Patients
The goal of this interventional double-blind study is to demonstrate the safety and efficacy of PRISM neurofeedback training within an MDD Anhedonia sample. The goals of this study include: 1.
- Trial name
- NCT05869708
- Testing
- Active RS-EFP
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- GrayMatters Health Ltd.
Training of Mental Health Professionals, Training of Frontline Health Workers
Measurement-Based Peer Supervision App for Non-Specialist Providers
The goal of this project is to enhance and evaluate the efficacy of a scalable digital solution designed to help train and support the work of non-specialist providers (NSPs), such as community health workers, to deliver therapy…
- Trial name
- NCT07082010
- Testing
- MBPS App
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Dimagi Inc.
Major Depressive Disorder
A Study of Ketamine in Patients With Treatment-resistant Depression
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
- Trial name
- NCT01627782
- Testing
- Ketamine
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Major Depressive Disorder
General Practice Research Database Seroquel XR Safety Study
The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Disorder
- Trial name
- GPRD SeroquelS (NCT01447082)
- Where
- Switzerland
- Volunteers
- 37,372 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Assessing Symptomatic Clinical Episodes in Depression
Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.
- Trial name
- ASCEND (NCT03595579)
- Testing
- AXS-05, Bupropion
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Axsome Therapeutics, Inc.
Study Adherence, Depressive Disorder
Message-Based Psychotherapy and Digital Treatment Sequences for Depression
This partnership between Talkspace and the University of Washington (UW) ALACRITY Center will determine how effective unlimited text-based psychotherapy for depression is when compared to once-a-week psychotherapy.
- Trial name
- NCT04513080
- Testing
- Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP), Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy
- Where
- United States
- Volunteers
- 1,184 people
- Sponsor
- Talkspace
Premenstrual Dysphoric Disorder
A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)
The study is a phase 1/2 study in two parts. In part 1, the primary objective is to assess the pharmacokinetics of UC1010 when administered subcutaneously as a single dose to healthy women.
- Trial name
- NCT01875718
- Testing
- UC1010
- Where
- Sweden
- Volunteers
- 146 people
- Sponsor
- Umecrine Mood AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.